:max_bytes(150000):strip_icc()/GettyImages-2166303621-d531caf645fa40429f9df33c6ef6a3d1.jpg "Bavarian Nordic Stock Jumps on Revenue Beat, Mpox Vaccine Order")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2166303621-d531caf645fa40429f9df33c6ef6a3d1.jpg)
KEY TAKEAWAYS
- Shares of Bavarian Nordic are surging in Danish trading after the company with the only approved mpox vaccine in the U.S. and Europe posted a quarterly revenue beat.
- Bavarian Nordic also announced a contract with an undisclosed European country to supply 440,000 doses of smallpox and mpox vaccine.
- The World Health Organization (WHO) declared the mpox outbreak in Africa a global health emergency last week.
Shares of Bavarian Nordic are surging 12% in Danish trading after the company with the only approved mpox vaccine in the U.S. and Europe posted a quarterly revenue beat and announced a huge vaccine order.
Bavarian Nordic, which reported second-quarter revenue of 1.43 billion Danish kroner ($212.9 million) that beat analysts’ consensus estimates, said it had signed a contract with an undisclosed European country to supply 440,000 doses of smallpox and mpox vaccine.
WHO Recently Declared Mpox Outbreak Global Health Emergency
Last week, the World Health Organization (WHO) declared the mpox outbreak in Africa a global health emergency after a surge in recent cases in the Democratic Republic of Congo and some neighboring countries.
The order by the unnamed European country was “anticipated as part of the 2024 guidance,” Bavarian Nordic Chief Executive Officer (CEO) Paul Chaplin said, adding it “has no impact on the remaining vaccine capacity.”
Bavarian Nordic shares are up more than 45% in the past month.